Remedy Cell and Qureight collaborate to integrate deep learning platform into Phase 1b study of RC-0315 in IPF

HAIFA, Israel, and CAMBRIDGE, England, March 12, 2025 /PRNewswire/ — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, and Qureight Ltd, a Core Imaging Laboratory with deep-learning analytics, , have partnered to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF).

The primary objective of the RC-0315 Phase 1b clinical study is to measure drug safety and tolerability. The study’s exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples.  

• RC-0315 therapeutic effect is attributed to its multi-target approach which enables a regenerative solution for complex fibrotic conditions.
• Qureight’s deep learning imaging platform will allow precise analysis of localised sections of the lungs to monitor RC-0315’s effect.

IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis, it is characterised by interstitial lung tissue becoming thick and stiff with an excessive buildup of collagen. The degenerative progression of the condition results in a steady deterioration of lung function, escalating respiratory problems, and a significant reduction in overall quality of life. Despite the considerable impact of these diseases, current therapeutic options remain limited in both efficacy and scope, creating an urgent need for innovative approaches.

RC-0315 has the potential to fulfil this unmet clinical need by repairing some of the lung tissue damage and restoring pulmonary function. It is a novel multifactorial, multi-proteinacious therapy that hits multiple IPF-associated targets simultaneously. It works by identifying several active proteins that hit relevant lung-tissue molecular targets. The effect of hitting these molecular targets results in Ligand-Receptor Interactions, which is thought to be the basis of the treatment’s regenerative mechanism.

Integrating their deep-learning technology in the clinical phase study, Qureight will be providing full end-to-end imaging core lab services, including site qualification, data handling, quality control (QC) and deep learning AI image analysis. RC-0315 has a novel application, and it will be instilled directly into a chosen lung segment by bronchoscopy. Qureight will apply its innovative AI modelling techniques to sub-sections of the lungs and look for localised changes in airways, fibrosis and blood vessels. This novel approach offers a more detailed precision-focused quantification of lung segments. These insights have the potential to provide crucial data for evaluating the efficacy of RC-0315 and, ultimately, drive progress toward more effective IPF treatments.

Ayelet Dilion Mashiah, CEO, Remedy Cell, said: “Remedy Cell has made significant strides bringing its proprietary technology from bench to clinical trials. We are so pleased to work with Qureight to allow a deeper understanding of RC-0315’s mechanism of action, and to bring further value to our Phase 1b trial.”  

Dr Muhunthan Thillai, CEO, Qureight, said: “Qureight’s AI-driven imaging analysis will allow a more precise assessment of RC-0315’s efficacy, providing the level of detail needed to understand the effects, and map this to patient outcomes. By focusing on localised changes within sub-sections of the lungs, we can move beyond traditional whole-lung assessments and gain a deeper understanding of the treatment’s impact on airways, fibrosis, and blood vessels. This can accelerate the development of more effective therapies for IPF patients.”

About Qureight 

Founded in 2018 and headquartered in Cambridge, UK, Qureight is a Core Imaging Laboratory, a rapidly-scaling techbio company deploying its technology on a global scale. The cloud-based, vendor-agnostic Core Imaging Platform is GDPR, HIPPA and NHS Digital compliant. The platform has ISO13485 and ISO27001 accreditation to interrogate clinical trial data. The team is led by co-founder & CEO Dr Muhunthan Thillai, a pulmonologist who trained in lung fibrosis.

About Remedy Cell

Remedy Cell is a clinical stage biopharmaceutical company revolutionising fibrotic disease treatment with cell-derived, cell-free breakthrough therapies. The company’s proprietary Activated Remedy Cell Secretome (ARcS) platform delivers multi-target, pro-regenerative solutions for complex fibrotic conditions. The company’s lead product, RC-0315, a first-in-class activated MSC-derived secretome therapy for IPF, has shown in definitive preclinical studies the potential to repair lung tissue and restore function.

Media Contacts:

Qureight: amy@somx.health

Remedy Cell: contact@remedycell.com

View original content:https://www.prnewswire.com/news-releases/remedy-cell-and-qureight-collaborate-to-integrate-deep-learning-platform-into-phase-1b-study-of-rc-0315-in-ipf-302399871.html

SOURCE Remedy Cell; Qureight Ltd